NasdaqGS:IBRXBiotechs
A Look At ImmunityBio (IBRX) Valuation After New European Anktiva Approval And International Expansion
ImmunityBio (IBRX) is back in focus after the European Commission granted conditional marketing authorization for Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer across 33 countries, expanding its global reach.
See our latest analysis for ImmunityBio.
The European approval comes at a time when ImmunityBio’s share price has already seen strong momentum, with a 7 day share price return of 46.34% and a 90 day share price return of 304.65%, while the 1 year total...